- Advanced search
- Immuno Portal
- Malaria Portal
Ligand id: 7426
View more information in the IUPHAR Pharmacology Education Project: lenvatinib
Molecular properties generated using the CDK
|No information available.|
|Summary of Clinical Use|
|Lenvatinib's first approval (in 2015) was for use in treating patients with progressive, differentiated thyroid cancer.
Marketed formulations contain lenvatinib mesylate (PubChem CID 11237762).
In May 2016, the US FDA expanded approval to include treatment (in combination with everolimus) of advanced renal cell carcinoma following one prior anti-angiogenic therapy. FDA approval was further expanded in August 2018 to include use as a first-line treatment for unresectable hepatocellular carcinoma (HCC), based on results from trial NCT01761266 . These results showed that lenvatinib was non-inferior to sorafenib in these patients. In Europe lenvatinib was granted EMA orphan designation as an HCC therapy in 2015.
Visit ClinicalTrials.gov to view currently registered drug trials assessing lenvatinib's effectiveness in treating additional types of cancer.
|Mechanism Of Action and Pharmacodynamic Effects|
|Lenvatinib is an inhibitor of all three VEGFR tyrosine kinases . Inhibits vascular endothelial growth factor (VEGF)-stimulated neo-angiogenesis and may therefore reduce the vascularisation which underpins and supports tumour development and growth.|
For extended ADME data see the following:
Electronic Medicines Compendium (eMC)
European Medicines Agency (EMA)